Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma

Ohga Saiji, Katsumasa Nakamura, Yoshiyuki Shioyama, Tomonari Sasaki, Tadamasa Yoshitake, Kazushige Atsumi, Kotaro Terashima, Kaori Asai, Keiji Matsumoto, Hiroshi Yoshikawa, Yo Ichi Kawano, Hiroshi Honda

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML) is a rare disease. The purpose of this study was to evaluate the treatment outcome and patterns of failure of patients with early-stage POAML treated with radiotherapy. Patients and Methods: From 1995 to 2008, 53 patients with early-stage POAML were reviewed. Tumors were categorized as either superficial or mass-forming type. In principle, superficial lesions (n=11) were treated with 24 Gy, while the mass-forming lesions (n=42) were irradiated with 30 Gy. The median follow-up period was 3.9 years. Results: All four cases of relapse had mass-forming lesions. The 5-year overall and progression-free survival rates were 100% and 91.5%, respectively. Although 30 patients experienced grade 2 or 3 late adverse events, no patients had radiation-related retinopathy. Conclusion: Early-stage POAML can be well-controlled with radiotherapy. However, the risk of distant relapse should be noted, in particular, for mass-forming tumors.

Original languageEnglish
Pages (from-to)5575-5578
Number of pages4
JournalAnticancer research
Volume33
Issue number12
Publication statusPublished - Dec 1 2013

Fingerprint

Marginal Zone B-Cell Lymphoma
Radiotherapy
Recurrence
Rare Diseases
Disease-Free Survival
Neoplasms
Survival Rate
Radiation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. / Saiji, Ohga; Nakamura, Katsumasa; Shioyama, Yoshiyuki; Sasaki, Tomonari; Yoshitake, Tadamasa; Atsumi, Kazushige; Terashima, Kotaro; Asai, Kaori; Matsumoto, Keiji; Yoshikawa, Hiroshi; Kawano, Yo Ichi; Honda, Hiroshi.

In: Anticancer research, Vol. 33, No. 12, 01.12.2013, p. 5575-5578.

Research output: Contribution to journalArticle

Saiji, O, Nakamura, K, Shioyama, Y, Sasaki, T, Yoshitake, T, Atsumi, K, Terashima, K, Asai, K, Matsumoto, K, Yoshikawa, H, Kawano, YI & Honda, H 2013, 'Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma', Anticancer research, vol. 33, no. 12, pp. 5575-5578.
Saiji, Ohga ; Nakamura, Katsumasa ; Shioyama, Yoshiyuki ; Sasaki, Tomonari ; Yoshitake, Tadamasa ; Atsumi, Kazushige ; Terashima, Kotaro ; Asai, Kaori ; Matsumoto, Keiji ; Yoshikawa, Hiroshi ; Kawano, Yo Ichi ; Honda, Hiroshi. / Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. In: Anticancer research. 2013 ; Vol. 33, No. 12. pp. 5575-5578.
@article{d5c5c0424d5948bea168e9b052974379,
title = "Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma",
abstract = "Background: Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML) is a rare disease. The purpose of this study was to evaluate the treatment outcome and patterns of failure of patients with early-stage POAML treated with radiotherapy. Patients and Methods: From 1995 to 2008, 53 patients with early-stage POAML were reviewed. Tumors were categorized as either superficial or mass-forming type. In principle, superficial lesions (n=11) were treated with 24 Gy, while the mass-forming lesions (n=42) were irradiated with 30 Gy. The median follow-up period was 3.9 years. Results: All four cases of relapse had mass-forming lesions. The 5-year overall and progression-free survival rates were 100{\%} and 91.5{\%}, respectively. Although 30 patients experienced grade 2 or 3 late adverse events, no patients had radiation-related retinopathy. Conclusion: Early-stage POAML can be well-controlled with radiotherapy. However, the risk of distant relapse should be noted, in particular, for mass-forming tumors.",
author = "Ohga Saiji and Katsumasa Nakamura and Yoshiyuki Shioyama and Tomonari Sasaki and Tadamasa Yoshitake and Kazushige Atsumi and Kotaro Terashima and Kaori Asai and Keiji Matsumoto and Hiroshi Yoshikawa and Kawano, {Yo Ichi} and Hiroshi Honda",
year = "2013",
month = "12",
day = "1",
language = "English",
volume = "33",
pages = "5575--5578",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma

AU - Saiji, Ohga

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Sasaki, Tomonari

AU - Yoshitake, Tadamasa

AU - Atsumi, Kazushige

AU - Terashima, Kotaro

AU - Asai, Kaori

AU - Matsumoto, Keiji

AU - Yoshikawa, Hiroshi

AU - Kawano, Yo Ichi

AU - Honda, Hiroshi

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background: Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML) is a rare disease. The purpose of this study was to evaluate the treatment outcome and patterns of failure of patients with early-stage POAML treated with radiotherapy. Patients and Methods: From 1995 to 2008, 53 patients with early-stage POAML were reviewed. Tumors were categorized as either superficial or mass-forming type. In principle, superficial lesions (n=11) were treated with 24 Gy, while the mass-forming lesions (n=42) were irradiated with 30 Gy. The median follow-up period was 3.9 years. Results: All four cases of relapse had mass-forming lesions. The 5-year overall and progression-free survival rates were 100% and 91.5%, respectively. Although 30 patients experienced grade 2 or 3 late adverse events, no patients had radiation-related retinopathy. Conclusion: Early-stage POAML can be well-controlled with radiotherapy. However, the risk of distant relapse should be noted, in particular, for mass-forming tumors.

AB - Background: Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML) is a rare disease. The purpose of this study was to evaluate the treatment outcome and patterns of failure of patients with early-stage POAML treated with radiotherapy. Patients and Methods: From 1995 to 2008, 53 patients with early-stage POAML were reviewed. Tumors were categorized as either superficial or mass-forming type. In principle, superficial lesions (n=11) were treated with 24 Gy, while the mass-forming lesions (n=42) were irradiated with 30 Gy. The median follow-up period was 3.9 years. Results: All four cases of relapse had mass-forming lesions. The 5-year overall and progression-free survival rates were 100% and 91.5%, respectively. Although 30 patients experienced grade 2 or 3 late adverse events, no patients had radiation-related retinopathy. Conclusion: Early-stage POAML can be well-controlled with radiotherapy. However, the risk of distant relapse should be noted, in particular, for mass-forming tumors.

UR - http://www.scopus.com/inward/record.url?scp=84891445778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891445778&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 5575

EP - 5578

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -